Copenhagen, 2015-12-31 10:51 CET (GLOBE NEWSWIRE) -- Copenhagen, 31 December 2015 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand announces the total number of shares and voting rights in the company at the end of a calendar month in which changes to the share capital have occurred.
With reference to Company Announcement no. 52 / 2015 dated 4 December 2015 informing of an increase in the share capital and the voting rights after exercise of employee warrants, the table below provides the total number of shares and voting rights in Zealand as of 31 December 2015.
|
Date |
Total number of shares (nominal value of DKK 1 each) |
Share capital (nominal value in DKK) |
Total number of votes |
| 31 Dec 2015 | 24,352,769 | 24,352,769 | 24,352,769 |
●●●●●
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® by Sanofi and under regulatory review in the US. The license agreement with Sanofi covers also LixiLan, which is a single-product combination of lixisenatide and insulin glargine (Lantus®). LixiLan has been submitted for regulatory priority review in the US and regulatory submission is expected in the EU in Q1 2016.
The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; ZP2929 for diabetes/obesity in Phase I; as well as several preclinical peptide therapeutics.
The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
